Neuroscan System For Providers Jun 2026

: A flagship piece of technology that recently received FDA approval . It uses Magnetoencephalography (MEG) to measure the tiny magnetic fields produced by brain activity, offering a non-invasive way to map critical brain functions before surgery.

In the evolving landscape of brain health, subjective symptom reporting—while valuable—often leaves providers navigating diagnostic ambiguity. The NeuroScan System bridges this gap, transforming how clinicians assess, document, and treat neurological and psychiatric conditions by translating cortical electrical activity into actionable, objective data. neuroscan system for providers

If a scan reveals that a patient’s anxiety is driven by hyper-arousal (excess beta waves), the provider might prioritize interventions that lower cortical arousal, such as specific neurofeedback protocols or non-stimulant medications. Conversely, if a scan shows hypo-arousal, a different therapeutic approach is indicated. For psychiatrists, this is particularly valuable in guiding psychopharmacology, potentially reducing the months or years often spent adjusting medications through trial and error. Furthermore, the system provides a baseline measurement, allowing providers to objectively track progress over time. Repeating the scan after three months of treatment offers concrete proof of efficacy, guiding the decision to continue, modify, or cease a specific treatment plan. : A flagship piece of technology that recently

As of 2025, QEEG (CPT 95716) and prolonged EEG monitoring (CPT 95705–95726) are reimbursable for specific indications (epilepsy, encephalopathy, traumatic brain injury, and selected psychiatric disorders with cognitive dysfunction). Pre-authorization is recommended for non-seizure indications. Many providers utilize a hybrid model: bill the technical component (recording) in-house and refer interpretation to a partnering neurologist. The NeuroScan System bridges this gap, transforming how